Abstract: The present disclosure provides a transverse magnetic flux motor having a stator and a rotor. The stator adopts a tooth and yoke separation structure. Multiple stator teeth are arranged at intervals along the circumferential direction of a stator yoke. The stator teeth or the stator yoke are wound with a stator winding. The rotor is provided on one side of the stator near the stator teeth in the axial direction, and has a back iron and multiple permanent magnets arranged in sequence along the circumferential direction. The permanent magnets are magnetized along the axial direction, and the polarities of adjacent permanent magnets are different from one another.

Abstract: Disclosed are single domain antibodies that specifically bind to human LAG3 or a fragment or functional domain thereof, and compositions containing the single domain antibodies. Also disclosed are methods of preparing the antibodies and use of the antibodies for treating and/or preventing one or more conditions such as lymphoma, non-small cell lung cancer (NSCLC), gastric cancer, hepatocellular carcinoma, renal cell carcinoma, bladder cancer, squamous cell carcinoma of the head and neck, melanoma, or glioblastoma.

Abstract: Disclosed herein are combinational therapies for diabetes comprising a first effective amount of one or more first active ingredients selected from the group consisting of GLP-1 and GLP-1 analogs and a second effective amount of one or more second active ingredients selected from the group consisting of insulin and insulin analogs.

Abstract: A rotating motor and a fan are provided. A first bearing seat, a second bearing seat and a plurality of support rods of the motor are arranged to form a supporting frame of the motor. Accordingly, the coaxiality between the first bearing seat and the second bearing seat can be ensured. The motor has a rotor. The outer diameter of the permanent magnet of the rotor is disposed to be greater than or equal to the outer diameter of a second bearing of the rotor. The outer diameter of a first bearing of the rotor is disposed to be greater than or equal to the outer diameter of the permanent magnet of the rotor. Accordingly, the entire rotor of the rotating motor can be directly mounted on the supporting frame.

Abstract: A rotating motor and a fan are provided. In the rotating motor, by arranging a first bearing seat, a second bearing seat, and a plurality of support rods to form the supporting frame, the coaxiality between the first bearing seat and the second bearing seat can be ensured to reduce the accumulated tolerance of assembly. In addition, the motor has a stator having stator teeth. The inner diameter of the inner circular hole of the stator teeth is disposed to be larger than the outer diameter of the second bearing seat.

Abstract: The present disclosure provides a transverse magnetic flux motor having a stator and a rotor. The stator adopts a tooth and yoke separation structure. Multiple stator teeth are arranged at intervals along the circumferential direction of a stator yoke. The stator teeth or the stator yoke are wound with a stator winding. The rotor is provided on one side of the stator near the stator teeth in the axial direction, and has a back iron and multiple permanent magnets arranged in sequence along the circumferential direction. The permanent magnets are magnetized along the axial direction, and the polarities of adjacent permanent magnets are different from one another.

Abstract: Disclosed herein is a pharmaceutical composition containing a recombinant human GLP-1 peptide and use thereof. The human GLP-1 peptide and the pharmaceutical composition can be used for preventing or treating obesity, bulimia, and/or overweight. Other related uses include weight management (e.g. inducing weight loss), slowing stomach emptying, increasing satiety, etc.

Abstract: Disclosed herein is an insulinotropic peptide multi-dose aqueous parenteral pharmaceutical composition and use thereof. A long-term storage formulation of the insulinotropic peptide can be obtained via the method of the present disclosure. The pharmaceutical composition of the present disclosure comprises: insulinotropic peptide, insulinotropic peptide analogue and derivative; pharmaceutically acceptable tonicity modifier (stabilizer); pharmaceutically acceptable preservative; and pharmaceutically acceptable dissolution enhancer and pharmaceutically acceptable buffer solution. The pharmaceutical composition of the insulinotropic peptide is used in the preparation of drugs for treating diabetes and adiposis.

Abstract: Exendins or exendin analogs modified by one or more PEG derivatives that may be linked to one or more amino acids of the exendins or exendin analogs are provided. The PEG derivatives may have branched structure set forth in any one of formulas I-IV. Compositions including the PEG derivative modified exendin or exendin analog, methods of making or administering the modified exendin or exendin analog, and various uses thereof are also provided.

Abstract: Exendins or exendin analogs modified by one or more PEG derivatives that may be linked to one or more amino acids of the exendins or exendin analogs are provided. The PEG derivatives may have branched structure set forth in any one of formulas I-IV. Compositions including the PEG derivative modified exendin or exendin analog, methods of making or administering the modified exendin or exendin analog, and various uses thereof are also provided.